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26:442–50.Early Intravenous Beta-
Blockade Before Primary
Percutaneous Coronary
Intervention Gives Major
Beneﬁts, Apparently
Without Side EffectsThe paper by Pizarro et al. (1) gives strong support
to the concept of very early low-cost intravenous
beta-blockade for primary percutaneous coronary
intervention (pPCI) and makes metoprolol the
agent of choice. When metoprolol was given to
patients with acute myocardial infarction (AMI) in
Killip class #II ST-segment elevation myocardial
infarction undergoing pPCI, there were fewer heart
failure admissions. The number needed to treat to
avoid 1 implantable cardioverter-deﬁbrillator was
only 8. Unexpectedly, there was no indication of
any side effects of beta-blockade. Were there really
none?
In the COMMIT (Clopidogrel and Metoprolol
in Myocardial Infarction Trial) study of 45,852 pa-
tients admitted to 1,250 hospitals within 24 h of
suspected AMI, patients were randomly allocated
metoprolol (up to 15 mg intravenous, then 200 mg
oral daily; n ¼ 22,929) or matching placebo (n ¼
22,923) (2). The use of early beta-blocker therapy
in AMI reduced the risks of reinfarction and ven-
tricular ﬁbrillation, yet cardiogenic shock was a
major side effect. Pizarro et al. (1) suggested starting
beta-blocker therapy only when the hemodynamic
condition had stabilized.
Yusuf (3) analyzed 28 trials involving approxi-
mately 27,500 patients during suspected early AMI.
Overall, he concluded that intravenous plus oral
beta-blockade reduced the risk for early death,
reinfarction, and ventricular ﬁbrillation by approxi-
mately 15% (3). He suggested that the reduction in
mortality was greatest for those treated within 2 h
of pain. The treated group had few side effects,
namely reversible and nonfatal heart block and
hypotension.
Thus in 2 large studies, beta-blockade had side-
effects to which clinicians should be alerted when
considering the use of beta-blockers for early AMI.*Lionel H. Opie, MD, DPhil
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Postgrad Med 1988;Spec No:90–5.REPLY: Early Intravenous Beta-Blockade
Before Primary Percutaneous Coronary
Intervention Gives Major Beneﬁts Apparently
Without Side EffectsWe appreciate the comment by our admired Professor
Opie regarding the potential side effects of early
intravenous (IV) beta-blockers in patients with
ST-segment elevation myocardial infarction (STEMI).
Our paper described the long-term follow-up of pa-
tients in the METOCARD-CNIC (Effect of Metoprolol
in Cardioprotection During an Acute Myocardial
Infarction) trial (1). The acute effects of IV metoprolol
in this trial were reported in a previous publication
(2). In the ﬁrst publication, we described the inci-
dence of adverse events during admission (those that
can be ascribed to an acute single administration of IV
metoprolol before primary angioplasty): death during
admission (2.1% vs. 2.3% in IV metoprolol vs. control,
respectively), advanced atrioventricular block (0.7%
vs. 1.5%), cardiogenic shock (4.3% vs. 5.4%), and
ventricular tachycardia/ﬁbrillation (3.6% vs. 7.7%).
Thus, it is not correct that there were no side effects
of beta-blockade in our study; rather, we presented
that metoprolol was not associated with an excess
number of these side effects.
The role of early IV beta-blockade in STEMI was
mostly evaluated long ago, and the side effect proﬁle
has been dramatically changed within the last few
years. The METOCARD-CNIC trial was the ﬁrst ran-
domized trial performed in patients with STEMI un-
dergoing reperfusion by primary angioplasty. One of
Dr. Opie’s references to support the potential increase
in side effect frequency is from Yusuf reporting a
